Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (split virion), inactivated, quadrivalent
- Development stage
- Approved
- Lead developer
- Jiangsu gdk Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The influenza vaccine (split virion), inactivated, quadrivalent developed by Jiangsu Watson Biotechnology is a seasonal influenza vaccine designed to provide broad protection against four circulating influenza strains. It is an inactivated, split-virion vaccine (IIV4) containing hemagglutinin (HA) and neuraminidase (NA) antigens from two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The virus particles are chemically disrupted (split) to reduce reactogenicity while maintaining the key immunogenic surface proteins. Clinical development has focused on evaluating the safety and immunogenicity of the vaccine in healthy individuals across multiple age groups, including toddlers aged 6–35 months and individuals aged 3 years and older, following WHO-recommended strain compositions for seasonal protection.
- Other names
- IIV4IIV-4IIV 4quadrivalent influenza vaccine (split virion), inactivated4价流感病毒裂解疫苗
02
Targets
HA (Hemagglutinin)HA (Influenza B virus hemagglutinin (HA) glycoprotein (Victoria lineage))Neuraminidase
Beyond the preview
Go deeper on influenza vaccine (split virion), inactivated, quadrivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (split virion), inactivated, quadrivalent.